Another limitation is related to the timing of the inclusion period used in this study; practically no patient in this cohort received SGLT2 inhibitors as heart failure therapy at the time point of the TTE since SGLT2 inhibitors were introduced into routine clinical care for heart failure patients afterward. Here, SLC5A2 is linked to heart failure.